Join us on November 12 as we dive into the results of the #PEERLESS RCT!
Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This symposium will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
Join the webinar Nov 12th!
Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This symposium will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This symposium will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
Join us Tuesday, 11/12 for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This webinar will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the PEERLESS randomized controlled trial results. This session will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
TONIGHT: The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This webinar will explore the RCT outcomes and offer valuable clinical insights into the future of PE intervention and patient care. https://bit.ly/3Uowje9
Join us for a recap of The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This session explores the RCT outcomes and offers valuable clinical insights into the future of PE intervention and patient care Watch: https://lnkd.in/dEeVmvfp
Join us for a recap of The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the results of the PEERLESS randomized controlled trial. This session explores the RCT outcomes and offers valuable clinical insights into the future of PE intervention and patient care Watch: https://lnkd.in/dEeVmvfp
🔍 Review clinical thyroidology research presented at the 2023 ATA's Annual Meeting in D.C. Highlighting innovative studies answering clinical questions and impacting patient care in the Clinical Year in Review! https://ow.ly/w1rl50QIhHV #ThyroidResearch
Exploring the landscape of clinical trials in #PulmonaryFibrosis! Liam Galvin kicked off our session by shedding light on the complexities and challenges faced in research and clinical trials for both PF and its symptoms. John K. Solheim, Wendy Adams, Farrell Simon, Brian Lee, PharmD, and Elisabetta Renzoni discussed how cooperation between patients, clinicians, and industry experts can help address these challenges and pave the way for improved trials and patient empowerment. #PFSUMMIT24 #ClinicalTrials
Clinical trials can be pivotal in a patient's care. When patients know they can receive free treatments, they're more willing to participate in important clinical trials. Hear more from Johnson & Johnson Innovative Medicine's Matthew L. Boyd, at the #BlackHealthMatters Summit as he shares why diversity in clinical trials is vital to healthcare and patients. Watch the full session now: https://bit.ly/3KaQOpb Session sponsored by Research Includes Me | Johnson & Johnson Innovative Medicine #ClinicalTrialDiversity #ClinicalTrials #BHMSpringSummitRewind24
